Results 161 to 170 of about 212,475 (307)
PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer Immunotherapy
The PBAP‐gE complex anchors gE antigen to PD‐L1 on tumor cells. Vaccine‐induced anti‐gE antibodies simultaneously engage FcγRIIIa on NK cells and tumor‐bound PBAP‐gE, triggering NK cell activation and antibody‐dependent cellular cytotoxicity, thereby selectively eliminating PD‐L1–expressing tumor cells.
Huixin Gao +24 more
wiley +1 more source
Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma
Researchers discovered that therapy‐induced loss of RD3 protein in neuroblastoma triggers a dangerous shift: cancer cells become more stem‐like, invasive, and resistant to treatment while evading immune detection. RD3 loss suppresses antigen presentation and boosts immune checkpoints, creating an immune‐silent environment.
Poorvi Subramanian +7 more
wiley +1 more source
Dectin-1 epigenetic reprogramming rescues senescent-like Treg function in allergic asthma. [PDF]
Sun X +7 more
europepmc +1 more source
This study delineates macrophage heterogeneity along the acute kidney injury to chronic kidney disease transition. Single‐cell RNA sequencing reveals a TRAP5+ scar‐associated macrophage subset driven by Spp1–Cd44 signaling and mitochondrial metabolic reprogramming.
Chenxi Wang +13 more
wiley +1 more source
Targeting tumor-infiltrating regulatory T cells based on immunometabolism. [PDF]
Li N, Tian D.
europepmc +1 more source
The engineered TF‐Fe@LC nanoplatform programs paraptotic death via multipath ROS amplification that disrupts redox homeostasis, provoking mitochondrial dysfunction, autophagic blockade, and ER stress. This caspase‐independent process elicits robust immunogenic cell death, combining with αPD‐L1 to activate systemic CD8+ T‐cell immunity and suppress ...
Zhe Yu +9 more
wiley +1 more source
The relativity of regulatory T cell suppression modes. [PDF]
Bai L, Choudhary V, Feng Y.
europepmc +1 more source
We developed a macrophage‐based therapeutic platform, termed trackable tolerogenic macrophages (TTM), for dual‐function immunomodulation and visualization in vivo. TTM cells were engineered to overexpress PD‐L1, incorporate bioorthogonal cell surface tags, and load rapamycin for sustained release.
Yihui Wang +14 more
wiley +1 more source

